21 C.F.R. PART 601--LICENSING
TITLE 21--Food and Drugs
CHAPTER I--FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER F--BIOLOGICS
PART 601--LICENSING
Subpart A--GENERAL PROVISIONS
|
Applications for biologics licenses; procedures for filing.
|
|
|
Issuance and denial of license.
|
|
|
Publication of revocation.
|
|
Subpart B--[RESERVED]
Subpart C--BIOLOGICS LICENSING
|
Changes to an approved application.
|
|
|
Regulatory submissions in electronic format.
|
|
|
Foreign establishments and products: samples for each importation.
|
|
|
Biologics licenses; issuance and conditions.
|
|
|
Products under development.
|
|
|
Products in short supply; initial manufacturing at other than licensed location.
|
|
|
Review procedures to determine that licensed biological products are safe, effective, and not misbranded under prescribed, recommended, or suggested conditions of use.
|
|
|
Reclassification procedures to determine that licensed biological products are safe, effective, and not misbranded under prescribed, recommended, or suggested conditions of use.
|
|
|
Annual reports of postmarketing pediatric studies.
|
|
Subpart D--DIAGNOSTIC RADIOPHARMACEUTICALS
|
General factors relevant to safety and effectiveness.
|
|
|
Evaluation of effectiveness.
|
|
Subpart E--ACCELERATED APPROVAL OF BIOLOGICAL PRODUCTS FOR SERIOUS OR LIFE-THREATENING ILLNESSES
|
Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
|
|
|
Approval with restrictions to assure safe use.
|
|
|
Postmarketing safety reporting.
|
|
|
Termination of requirements.
|
|
Subpart F--CONFIDENTIALITY OF INFORMATION
|
Confidentiality of data and information in an investigational new drug notice for a biological product.
|
|
|
Confidentiality of data and information in applications for biologics licenses.
|
|
Subpart G--POSTMARKETING STUDIES
|
Annual progress reports of postmarketing studies.
|
|
Subpart H--APPROVAL OF BIOLOGICAL PRODUCTS WHEN HUMAN EFFICACY STUDIES ARE NOT ETHICAL OR FEASIBLE
|
Approval based on evidence of effectiveness from studies in animals.
|
|
|
Postmarketing safety reporting.
|
|
|
Termination of requirements.
|
|